S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   384.22 (+1.11%)
AAPL   152.57 (+2.50%)
MSFT   324.35 (+0.37%)
FB   316.92 (+1.51%)
GOOGL   2,916.98 (-0.25%)
TSLA   1,077.04 (+3.78%)
AMZN   3,446.57 (+1.59%)
NVDA   249.41 (+2.00%)
BABA   169.79 (+0.33%)
NIO   40.79 (+3.76%)
CGC   12.99 (+1.64%)
GE   105.26 (+1.36%)
AMD   121.16 (-0.92%)
MU   69.58 (+1.96%)
T   25.55 (+1.96%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.18 (+0.49%)
BA   207.85 (+0.60%)
AMC   35.23 (+1.35%)
S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   384.22 (+1.11%)
AAPL   152.57 (+2.50%)
MSFT   324.35 (+0.37%)
FB   316.92 (+1.51%)
GOOGL   2,916.98 (-0.25%)
TSLA   1,077.04 (+3.78%)
AMZN   3,446.57 (+1.59%)
NVDA   249.41 (+2.00%)
BABA   169.79 (+0.33%)
NIO   40.79 (+3.76%)
CGC   12.99 (+1.64%)
GE   105.26 (+1.36%)
AMD   121.16 (-0.92%)
MU   69.58 (+1.96%)
T   25.55 (+1.96%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.18 (+0.49%)
BA   207.85 (+0.60%)
AMC   35.23 (+1.35%)
S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   384.22 (+1.11%)
AAPL   152.57 (+2.50%)
MSFT   324.35 (+0.37%)
FB   316.92 (+1.51%)
GOOGL   2,916.98 (-0.25%)
TSLA   1,077.04 (+3.78%)
AMZN   3,446.57 (+1.59%)
NVDA   249.41 (+2.00%)
BABA   169.79 (+0.33%)
NIO   40.79 (+3.76%)
CGC   12.99 (+1.64%)
GE   105.26 (+1.36%)
AMD   121.16 (-0.92%)
MU   69.58 (+1.96%)
T   25.55 (+1.96%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.18 (+0.49%)
BA   207.85 (+0.60%)
AMC   35.23 (+1.35%)
S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   384.22 (+1.11%)
AAPL   152.57 (+2.50%)
MSFT   324.35 (+0.37%)
FB   316.92 (+1.51%)
GOOGL   2,916.98 (-0.25%)
TSLA   1,077.04 (+3.78%)
AMZN   3,446.57 (+1.59%)
NVDA   249.41 (+2.00%)
BABA   169.79 (+0.33%)
NIO   40.79 (+3.76%)
CGC   12.99 (+1.64%)
GE   105.26 (+1.36%)
AMD   121.16 (-0.92%)
MU   69.58 (+1.96%)
T   25.55 (+1.96%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.18 (+0.49%)
BA   207.85 (+0.60%)
AMC   35.23 (+1.35%)
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$625.19
+35.59 (+6.04 %)
(As of 10/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$589.13
$625.72
50-Day Range
$543.48
$680.96
52-Week Range
$441.00
$686.62
Volume
1.11 million shs
Average Volume
858,556 shs
Market Capitalization
$66.87 billion
P/E Ratio
11.23
Dividend Yield
N/A
Beta
0.16
30 days | 90 days | 365 days | Advanced Chart
Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals logo

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
9,123
Year Founded
1988

Sales & Book Value

Annual Sales
$8.50 billion
Cash Flow
$32.09 per share
Book Value
$102.91 per share

Profitability

Net Income
$3.51 billion
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$66.87 billion
Next Earnings Date
11/4/2021 (Confirmed)
Fiscal Year End
N/A
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

2.75 out of 5 stars

Medical Sector

43rd out of 1,374 stocks

Pharmaceutical Preparations Industry

18th out of 668 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -












Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals
.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, November 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its earnings results on Thursday, August, 5th. The biopharmaceutical company reported $25.80 earnings per share for the quarter, beating the consensus estimate of $8.81 by $16.99. The biopharmaceutical company earned $5.14 billion during the quarter, compared to the consensus estimate of $3.90 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 50.43% and a net margin of 50.11%.
View Regeneron Pharmaceuticals' earnings history
.

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, REGN shares have increased by 34.5% and is now trading at $625.19.
View which stocks have been most impacted by COVID-19
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals announced that its Board of Directors has approved a share repurchase plan on Tuesday, November 5th 2019, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

What price target have analysts set for REGN?

16 analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' shares. Their forecasts range from $565.00 to $842.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $703.75 in the next year. This suggests a possible upside of 12.6% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.44%), Chevy Chase Trust Holdings Inc. (0.21%), New York State Teachers Retirement System (0.12%), Virginia Retirement Systems ET AL (0.11%), Pinnacle Associates Ltd. (0.09%) and DekaBank Deutsche Girozentrale (0.09%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Westpac Banking Corp, Virginia Retirement Systems ET AL, DNB Asset Management AS, Strs Ohio, Pinnacle Associates Ltd., New York State Teachers Retirement System, and Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Assenagon Asset Management S.A., Adams Diversified Equity Fund Inc., Robeco Institutional Asset Management B.V., DekaBank Deutsche Girozentrale, Moody Lynn & Lieberson LLC, Anderson Hoagland & Co., and Grandfield & Dodd LLC.
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $625.19.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $66.87 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.